RAPP SCHEDULE 13G/A: SEC filing
Cormorant Asset Management, LP and Bihua Chen
Filed with the SEC on · accession 0001172661-26-005299
RAPP filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Cormorant Asset Management, LP and Bihua Chen filed an amended Schedule 13G reporting beneficial ownership of 2,457,521 shares, or 5.12%, of Rapport Therapeutics, Inc. common stock as of September 30, 2026.
Summary of the filing
Cormorant Asset Management, LP and Bihua Chen filed an amended Schedule 13G reporting beneficial ownership of 2,457,521 shares, or 5.12%, of Rapport Therapeutics, Inc. common stock as of September 30, 2026. The filing is a passive investment disclosure with no stated intent to influence control of the company.
Key details
✦ Ask GOAX AI about this filing — what it means for RAPP, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for RAPP?
Click hereFrequently asked questions
What did RAPP file with the SEC on Nov 16, 2026?
RAPP filed a SCHEDULE 13G/A (SEC filing). Cormorant Asset Management, LP and Bihua Chen filed an amended Schedule 13G reporting beneficial ownership of 2,457,521 shares, or 5.12%, of Rapport Therapeutics, Inc. common stock as of September 30, 2026. The filing is a passive investment disclosure with no stated intent to influence control of the company.
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
Other RAPP SEC filings
- 10-Q · SEC filingNov 4, 2026
- 8-K · SEC filingNov 4, 2026
- 8-K · Secondary offeringOct 30, 2026
- 8-K · Fda approvalOct 20, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 12, 2026
- 8-K · SEC filingAug 5, 2026
- 10-Q · SEC filingAug 5, 2026
- 8-K · SEC filingJun 10, 2026
Get alerts when RAPP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days